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tumor express the specific mutations targets of biological agents, so 
chemotherapy is the only choice of treatment for these cases. Often 
elderly patients with advanced NSCLC have comorbidities, which 
prevent the administration of standard schedules of chemotherapy.
A new modality of chemotherapy administration is the 
metronomic schedule, based on the regular frequent use of lower 
doses of conventional drugs, proposed as an emerging alternative 
to conventional chemotherapy. Metronomic chemotherapy is 
sometimes more effective than the classic schedule, due to the 
continuous presence of lower doses of the drug in the patient; and 
it is also more tolerable, since the higher dose used in the classis 
schedule often limits the patient capacity to handle the side effects 
[3]. Furthermore, the cytostatic continuous action of metronomic 
administration can overcome drug resistance, assuring efficacy 
without great toxicity [3]. Carboplatin, paclitaxel and vinorelbine 
are the most utilized agents for lung cancer treatment, and the same 
agents are used also in metronomic schedules [4].
Quality of life (QoL) is an important prognostic factor in all 
cancer patients, especially in lung cancer [5]; patients with poor 
performance status (PS) aren’t fit for treatments, and they are 
candidates for palliative care only. Therefore, it is important to offer 
to these patients a first-line treatment that preserves QoL, limits 
toxicity, ensures the best possible response and allows patients to be 
fit for further treatments prolonging their overall survival (OS).
In our experience we have chosen to treat 41 elderly patients 
with advanced NSCLC with metronomic chemotherapy in first 
line, independently from their tumor histology, with the principal 
aim to preserve their QoL by reducing therapy toxicity. We have 
demonstrated, beyond a perfect adherence with the therapy and no 
grade 3 and 4 toxicities, a relevant clinical benefit for our cohort of 
patients, with an efficacy not inferior to that of traditional regimens, 
in terms of disease free survival (DFS) and OS.
Patients and Methods
We have retrospectively analyzed a cohort of 41 advanced 
NSCLC patients treated in our institution between 2009 and 2013. 
Abstract
Metastatic non small cell lung cancers (NSCLC) are diseases 
with poor prognosis and platinum-based doublet chemotherapy 
still remains their standard cure. Elderly patients often present 
comorbidities that limit the utilization of this chemotherapy; therefore 
these patients should have a first-line treatment with low toxicity 
and capable to preserve the quality of life (QoL) but, at the same 
time, to ensure the best possible response. Furthermore, a first-line 
treatment allows patients to be fit for further treatments, prolonging 
overall survival. At this regard, metronomic chemotherapy can be 
an optimal choice for elderly, able to improve QoL and to obtain an 
optimal palliation. We retrospectively studied a cohort of 41 elderly 
advanced NSCLC patients with different histotypes, treated with 
metronomic chemotherapy (weekly carbo-paclitaxel or vinorelbine 
as single agent) as first choice and we analyzed the tolerability, the 
impact on QoL and the efficacy of these schedules: no toxicity of 
3 and 4 grade was observed, together to a clinical benefit of 43%. 
We administered FACT-L test to evaluate QoL at baseline and 
after 4 months and found a significant improvement in all FACT-L 
parameters: physical, social, emotional and functional, confirming 
a QoL improvement. At a median follow-up of 20.2 months the 
progression free survival was of 6 months and the overall survival 
was of 15 months. These results suggest that metronomic 
chemotherapy can be an effective choice of treatment for elderly 
NSCLC patients and further trials with more patients are needed to 
confirm this proposal.
Keywords
Elderly, Carboplatin, Paclitaxel, Vinorelbine, Non-small cell lung 
cancer, Quality of life.
Introduction
Lung cancer is the leading cause of cancer-related death worldwide, 
with a five years survival rate of about 15%; approximately 85% of all 
cases are non small cell lung cancers (NSCLC) [1]. The identification 
of specific mutations has led in the last ten years to the development 
of molecular targeted agents, which have improved the overall 
survival of metastatic patients [2]. Unfortunately, not all types of lung 
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Toxicity and QoL were evaluated as primary endpoints: the 
first was graded according to the National Cancer Institute (NCI) 
- Common Toxicity Criteria for AE (version 3.0); the second was 
evaluated by administering version 2 Functional Assessment of 
Cancer Therapy - Lung (FACT-L) test to our patients [6-8]. FACT-L 
test is a 44-item questionnaire that measures multidimensional 
quality of life; all questions are rated on five-points ranging from 0 
(negative) to 4 (highly positive). Descriptive statistics was used to 
determine the overall QoL for patients at baseline and at 4 months. 
Matched t tests were conducted to discern whether the quality-of-life 
indicator (p < 0.05 was considered significant) differed from baseline 
to 4 months. Statistical analysis was performed using Graph Pad Prism 
5.0 (GraphPad Software Inc., San Diego, CA, USA). Overall response 
rate (ORR), clinical benefit (CB), progression free survival (PFS) and 
overall survival (OS) were evaluated as secondary endpoints. The 
ORR was reported with its 95% confidence interval. OS and PFS were 
calculated by the Kaplan-Meier product-limit method. Statistical 
evaluation was performed by means of the statistical software CRAN 
2.4.0.
Results
The clinical characteristics of all 41 patients were collected and 
All 41 patients had inoperable NSCLC (clinical stage assigned 
on the basis of the Seventh Edition of the TNM Classification for 
Lung Cancer) and median age 75 years (range 70-83), 30 males 
and 11 females. Eligibility criteria were the following: histologically 
measurable NSCLC with at least one measurable lesion according 
to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, 
minimal life expectancy of 16 weeks, serum creatinine within normal 
limits (creatinine clearance > 30 ml/min by the Cockroft and Gault 
formula), hemoglobin ≥10 g/L, white blood cell conts ≥ 3.5 × 109/L, 
absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelets ≥ 150 
× 109/L, total serum bilirubin ≤ 1.5× upper normal limit (UNL), 
transaminases  ≤ 2.0× upper normal limit (UNL) unless attributed 
to liver metastases. All patients carried out a total body computed 
tomography (CT) scan at baseline and every three cycles to assess 
tumor response. Tumor response and disease progression were 
assessed according to RECIST criteria. 25 patients were treated with 
weekly carboplatin AUC2 in association to paclitaxel (80 mg/mq 
weekly) d 1, 8,15 q28 for 3-4 courses and 16 patients with vinorelbine 
50 mg total dose d 1-3-5 q7 until diseae progression or unacceptable 
toxicity. Only 5 adenocarcinoma patients had epidermal growth 




Histotype Genre KPS Thoracic Stage MetastaticSite SRS WBR Palliative RT
1 ADC Male 80 IIA Liver, lymphnode - - -
2 SCC Female 70 IIB Liver, lymphnode - - -
3 SCC Male 70 IIIB Liver - - -
4 LCC Male 70 IIIB Bone, liver, lymphnode - - Bone
5 ADC Female 80 IIIA Brain + - Brain
6 ADC Male 70 IIIA Lymphnode, liver, controlateral lung - - -
7 ADC Male 70 IIIB Liver - - -
8 ADC Male 70 IIIB Liver, lymphnode - - -
9 ADC Male 70 IIIB Bone, liver - - -
10 ADC Male 80 IIIA Bone, liver - - -
11 SCC Male 70 IIIB Brain + - Brain
12 SCC Male 70 IIIB Bone, lymphnode - - -
13 SCC Male 70 IIIB Controlateral lung, liver - - -
14 ADC Male 80 IIIB Bone, liver - - -
15 LCC Female 70 IIIB Liver, bone,
lymphnode
- - -
16 SCC Male 80 IIIB Cutis, liver - - -
17 SCC Female 70 IIIB Bone - - -
18 SCC Male 70 IIIA Liver - - -
19 ADC Female 70 IIIB Controlateral lung, liver - - -
20 ADC Male 70 IIB Liver, bone - - -
21 SCC Male 70 IB Brain - + Brain
22 SCC Female 70 IIIB Controlateral lung, bone - - -
23 SCC Male 70 IIB Liver, lymphnode - - -
24 ADC Male 70 IIIB Liver, bone - - -
25 SCC Male 80 IIIA Liver - - -
26 SCC Male 70 IIIA Bone, liver - - -
27 SCC Male 60 IIIB Brain - + Brain
28 SCC Male 60 IIA Brain - + Brain
29 ADC Female 70 IIIB Bone, liver - - -
30 ADC Male 60 IIA Liver - - -
31 ADC Male 60 IIB Bone, liver - - Bone
32 SCC Male 60 IIIB Bone, liver - - Bone
33 LCC Female 70 IIA Bone, liver - - Bone
34 SCC Male 70 IIA Liver - - -
35 SCC Male 60 IIIA Liver, bone - - -
36 SCC Female 60 IIIA Brain - + Brain
37 SCC Female 60 IIA Bone - - Bone
38 SCC Female 70 IIIB Bone - - -
39 ADC Male 60 IIIB Bone - - Bone
40 SCC Male 70 IIIB Bone - - Bone
41 SCC Male 60 IIA Bone - - Bone
Table 1: Description of metastatic NSCLC patients. ADC (adenocarcinoma); SCC (squamous cell carcinoma); LCC (large cell carcinoma); KPS (Karnofsky performance 
status); SRS (stereotactic radiosurgery); WBR (whole brain radiotherapy); RT (radiotherapy).
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(12.2%) died due to causes not connected with tumors, while one 
patient is still alive. At a median follow-up of 20.2 months (range 
12.3-32.2) the overall survival (OS) was 15 months (95% CI, 14-17) 
and the progression free survival (PFS) was 6 months (95% CI, 5-9) 
(Figure 1).
Discussion
We have retrospectively selected a heterogeneous cohort of 
elderly patients with oligometastatic and multimetastatic NSCLC 
characterized by a performance status of 1/2, and demonstrated that 
metronomic schedule was more tolerable in these patients preserving 
their quality of life. At the same time, metronomic therapy was not 
inferior in terms of efficacy (evaluating DFS and OS) to the classic 
schedules.
Often elderly NSCLC patients are unfit for chemotherapy and a 
consensus on the best option for them doesn’t exist. Weekly carbo-
paclitaxel is a valid option for this kind of patients [9,10], while 
metronomic vinorelbine as single agent is an optimal choice of 
treatment for patients unsuitable for platinum in first line [11]. The 
majority of metronomic schedules in lung cancer are performed with 
platinum agents in association with taxanes. A recent study of 167 
patients (median age 65 years) compared the standard tri-weekly to 
the weekly schedule of carboplatin and paclitaxel in advanced NSCLC 
patients: toxicity was significantly decreased in the metronomic 
(weekly) arm, and for the first time this kind of administration 
has shown a better response than the tri-weekly standard schedule 
[12]. The Four Arms Comparative Study analyzed four standard 
platinum based regimens (with irinotecan, paclitaxel, gemcitabine or 
vinorelbine) to define the most effective schedule in first line, and the 
results demonstrated a similar efficacy among all these schedules [13]. 
In another study, AUC6 carboplatin was administered every 21 days 
with weekly paclitaxel (at the dose of 90 mg/mq) in a cohort of elderly 
patients, showing an higher efficacy respect the arm treated with 
monotherapy, but with an elevated incidence of febrile neutropenia 
[14].
We think that carbo-paclitaxel in a weekly administration can 
be a feasible and effective option for elderly, also in the presence of 
aggressive metastatic disease, all studies in fact conclude that the 
weekly regimen gives an advantage in toxicity, but not all of these 
studies demonstrate a comparable advantage in survival respect to 
the three weeks schedule [15]. We have chosen the minimal effective 
dose, based on metronomic theory, in order to minimize toxicity 
and to preserve the quality of life. The treatment with vinorelbine 
showed an efficacy comparable to carbo-paclitaxel in our cohort of 
patients. The maintenace of a costant lower dose of chemoterapeutics 
with a weekly schedule may be important in determining disease 
reduction and inducing less side effects. We found that no patient 
had G3 or G4 toxicity, with an optimal adherence to the treatment 
and no interruptions of the schedule; all the parameters of FACT-L 
test demonstrated a gain from baseline in terms of physical, social, 
emotional and functional well being.
The two prognostic factors that mainly influence long-term 
survival are the objective response after chemotherapy and the 
performance status [16]. In our cohort, although all patients had a 
performance status of 1/2, the overall response rate was 63.5% and 
the quality of life improved respect to baseline due to chemotherapy. 
The reason of the optimal efficacy of this weekly schedule is based 
on metronomic theory, whereby tumor response (or stable disease) 
is obtained when low dose of chemotherapy is administered with 
no intervals or in a short range of intervals [17]. The efficacy of 
metronomic therapy has been previously demonstrated by our 
group and by other authors in other settings of patients and in other 
kind of cancers, especially for elderly people [18,19]. Metronomic 
chemotherapy didn’t cause G3-4 neutropenia in our cohort of 
patients, contributing to preserve the quality of life, yet neutropenia 
chemotherapy-related is a prognostic factor for survival in patients 
with advanced NSCLC [1].
From our experience, we can suggest that first line metronomic 
listed (Table 1): 23 squamous cell carcinoma, 3 large cell carcinoma 
and 15 adenocarcinoma. No treatment-related death occurred. None 
of the patients required G-CSF (granulocyte-colony stimulating 
factors) for neutropenia or erythropoietin for anemia. Treatment was 
well tolerated, without any delay or dose reduction.
Toxicity was evaluated and resulted minimal in all patients and 
no adverse events of grade (G) 3 and 4 were observed, only G1 and G2 
toxicity was detected (Table 2). The following adverse events, classified 
as G1, occurred: neutropenia in 10 patients (24.39%), anemia in 20 
patients (48.78%), neuropathy in 30 patients (73.17%), asthenia in 
15 patients (36.58%) and alopecia in 39 patients (95.12%). The G2 
adverse events were: neutropenia in 5 patients (13.19%), anemia in 10 
patients (24.39%), asthenia in 10 patients (24.39%) and neuropathy 
in 5 patients (12.19%). No patients suffered for thrombocytopenia, 
mucositis, nausea or vomiting neither for febrile neutropenia. The 
quality of life of all patients was analyzed by FACT-L test at baseline 
and at 4 months (Table 3) and a significant modification was found 
in all parameters: physical well-being (p = 0.0002), social/family well-
being (p  =  0.001), emotional well-being (p  =  0.002) and functional 
well-being (p = 0.001), demonstrating a significant improvement in 
QoL from baseline to 4 months.
The average length of the treatment was 3 months, while the 
median response lenght was 6 months (95% CI, 5.2-7.8). One patient 
treated with carbo-paclitaxel achieved complete response (2.5%), and 
25 patients (12 treated with carbo-paclitaxel and 13 with vinorelbine) 
achieved partial responses (61%), 15 patients (37%) had stable disease. 
Only the patients who did not progress beyond six months have been 
considered for the clinical benefit, and resulted that 18 patients (44%) 
received a clinical benefit (Table 4). Overall response rate was 63.5% 
(95% CI, 58.1-72), and it was achieved in 26 patients including 1 
complete response (2.5%) and 25 partial responses (61%), while 15 
patients (37%) had stable disease and no patients had progression of 
the disease. Clinical benefit, observed in 18 patients, was 44% (95% 
CI, 36.2-51.5) (Table 4).
Thirtyfive patients died for tumor progression (85.4%), five 
Toxicity grade G1 G2 G3 G4








Trombocitopenia  -  - - -
Mucositis  - - - -








Nausea/vomiting  -  - - -
Alopecia 39 (95.12%) - - -
Table 2: Description of patient toxicity.
Quality of life: FACT L
Variable Baseline 4 months p-Value
Mean SD Mean SD
Physical Well-Being (PWB) 11.95 1.40 15.60 1.60 0.0002
Social/family Well-Being (SWB) 14.20 1.30 16.60 1.10 0.001
Emotional Well-Being (EWB) 14.00 1.34 16.20 1.40 0.002
Functional Well-Being (FWB) 12.70 1.20 14.10 1.50 0.001
Table 3: Data of quality of life by FACT-L test. SD: standard deviation.
Table 4: Clinical benefit (CB) of the patients (CR + PR + SD ≥ 6 months). CR: 
complete response; PR: partial response; SD: stable disease.
N = 41 %
CR 1 (1 lasting more than 6 months)  2.5% (2.5%)
PR 25 (11 lasting more than 6 months) 61% (26.8%)
SD 15 (6 lasting more than 6 months) 37% (14.7%)
CB 18 44%
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Figure 1: Kaplan-Meier curves of overall survival and of progression free survival in our cohort of metastatic NSCLC patients.
chemotherapy is an effective and less toxic alternative for every 
elderly NSCLC patient, preserving the quality of life, as demonstrated 
by the score of FACT-L test. These schedules, constituted by weekly 
carbo-paclitaxel and vinorelbine as single agent, are characterized by 
the lack of toxicity with no G3 and G4 side effects. The benefit has 
been demonstrated, although only in 41 patients with lung cancer, 
either for squamous cell cancer than for adenocarcinoma. Due to the 
small cohort of our patients and to the retrospective nature of our 
study, it should be necessary to perform greater prospective studies in 
which metronomic carbo-paclitaxel and vinorelbine as single agent at 
the used dosages are compared to the standard three weeks schedule, 
in order to find out whether our data can be confirmed.
Conclusions
First line metronomic chemotherapy is an effective and less toxic 
alternative for every elderly non small cell lung cancer patient, since 
this therapy preserves the quality of life and gives the same benefits 
as the classic schedule. Furthermore, metronomic chemotherapy is 
characterized by a significant decrease of toxicity and less side effects 
as compared to classic therapy.
Abbreviation Field
NSCLC: non small cell lung cancers; QoL: quality of life; PS: 
performance status; OS: overall survival; DFS: disease free survival; 
RECIST: response evaluation criteria in solid tumors; AUC: area 
under curve; ANC: absolute neutrophil count; UNL: upper normal 
limit; CT: computed tomography; EGFR: epidermal growth factor 
receptor; TKi: tyrosine kinase inhibitors; NCI: National Cancer 
Institute; FACT-L: functional assessment of cancer therapy – lung; 
ORR: overall response rate; CB: clinical benefit; PFS: progression free 
survival; G-CSF: granulocyte-colony stimulating factors; G: grade; CI: 
confidence interval.
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